Phase I study of Paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced non-small cell lung cancer.

Phase I study of Paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced non-small cell lung cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Phase I study of Paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced non-small cell lung cancer. Abstract Text:

David I Rosenthal,Clifton David Fuller,Mitchell Machtay,Kenneth M Algazy,Dan M Meyer,Larry R Kaiser,Denise A Yardley,Megan E Loiacano,David P Carbone,

BACKGROUND: Paclitaxel is active in non-small-cell lung cancer (NSCLC) and is a radiosensitizer with a dose-response relationship that depends more on duration of exposure than peak concentration. A continuous infusion prolongs exposure and may maximize the drug-radiation interaction. The goal of this National Cancer Institute-sponsored phase I study was to determine the feasibility and toxicity of a continuous infusion paclitaxel (24 hours/day, 7 days/week, 7 weeks total) concurrent with standard radiation therapy (RT) for locally advanced NSCLC. METHODS: Eligible patients had locally advanced (T4, N1-3, M0 or Tany, N2-3, M0) NSCLC, performance status less than or equal to 2, and adequate hematological, hepatic, renal, and pulmonary function. RT was given to a total dose of 64.8 Gy at 1.8 Gy/day. Paclitaxel was delivered by infusion beginning 48 hours before and then continuously throughout the 7 weeks of RT. The paclitaxel concentration was escalated in sequential dose cohorts ranging from 0.5 to 17 mg/m/d, and each contained at least three patients in a standard phase I design. RESULTS: Twenty-nine patients were enrolled. Significant grade 3+ toxicity was observed in one patient, who experienced grade 3 pneumonitis at the 6.5-mg/m/day dose level. This cohort was expanded, but none of four additional patients experienced significant toxicity. Three patients completed the 15-mg/m/day dose level without serious or dose-limiting toxicity. The two patients entered at the 17-mg/m/day dose level had grade 4 neutropenia requiring a delay in therapy of more than 1 week. The median survival of all patients was 12 months; however, 4 of 27 patients (15%) survived longer than 60 months (mean 63.4 months). CONCLUSION: The maximally tolerated and recommended phase II paclitaxel dose delivered by protracted continuous infusion is 15 mg/m/day when combined with thoracic RT. This schedule allows for the delivery of more total paclitaxel than other published regimens and may have less esophagitis than weekly paclitaxel regimens. This regimen has the potential to achieve a radiosensitizing serum concentration of paclitaxel continuously for 7 weeks without exceeding levels associated with neutropenia or neurotoxicity. There were four long-term survivors in this phase I study. These data suggest that continuous paclitaxel infusion with concurrent RT is safe and should be of interest to explore in combination with other cytotoxic or targeted therapies.

Phase I study of Paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced non-small cell lung cancer. Publishing Authors By Initials

DI Rosenthal,CD Fuller,M Machtay,KM Algazy,DM Meyer,LR Kaiser,DA Yardley,ME Loiacano,DP Carbone,

For similar diagnosis: prognosis: treatment outcome research abstracts see: diagnosis: prognosis: treatment outcome research

PUBMED ID PMID:

MEDLINE DATE:

Phase I study of Paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced non-small cell lung cancer. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Journal of thoracic oncology : official publicatio

VOLUME: 1

Page Numbers: 38-45

Journal Abbreviation:

ISSN: 1556-1380

DAY: 3

MONTH: Jan

YEAR: 2006

Phase I study of Paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced non-small cell lung cancer. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101274235

Phase I study of Paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced non-small cell lung cancer. Keywords Mesh Terms:

KEYWORDS: Treatment Outcome

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Phase I study of Paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced non-small cell lung cancer. Information

Substance Name: Paclitaxel

Registry Number: 33069-62-4

Grant and Affiliation Information for Phase I study of Paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced non-small cell lung cancer.

AFFILIATION: Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA. dirosenthal@mdanderson.org

Country: United States

AGENCY: United States NCRR

GRANT: NIH M01-RR01346

ACRONYM: RR

MEDLINETA: J Thorac Oncol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Phase I study of Paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced non-small cell lung cancer Related Publications

• Algorithm to estimate the Hurst exponent of high-dimensional fractals.
• Breast cancer: changing strategy for treatment.
• Calcium channels in chromaffin cells: focus on L and T types.
• Can distance education prepare future public health nutritionists? A case study.
• Chronic hypoxia up-regulates alpha1H T-type channels and low-threshold catecholamine secretion in rat chromaffin cells.
• Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters.
• Dendritic cell-induced memory T cell activation in nonlymphoid tissues.
• Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF.
• Fast exocytosis mediated by T- and L-type channels in chromaffin cells: distinct voltage-dependence but similar Ca2+ -dependence.
• Fatal stroke in a young cocaine drug addict: chemical hair analysis and cervical artery examination twenty months after death.
• Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism.
• Hypoalbuminemic and hypocholesterolemic effect of L-asparaginase (NSC-109,229) treatment in man--a preliminary report.
• Immune Activation and Increased Prevalence of Thrombosis in HIV Infection.
• Immunocell-array for molecular dissection of multiple signaling pathways in mammalian cells.
• Intraortic negative pressure suction during glue application.
• Is matching innate?
• L-type calcium channels in adrenal chromaffin cells: role in pace-making and secretion.
• METHYLTESTOSTERONE, RELATED STEROIDS, AND LIVER FUNCTION.
• Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.
• Ovarian endomyometrioma with atypias: description of a case.
• Phase I study of Paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced non-small cell lung cancer.
• Preliminary studies with dibromomannitol (NSC-94100) in patients with chronic myelogenous leukemia.
• Proteomics analysis in lung cancer: challenges and opportunities.
• Some observations of the behavior of amylase in relation to acute renal insufficiency.
• Spoken word frequency counts based on 1.6 million words in American English.
• The SV40 Large T Antigen-p53 Complexes Bind and Activate the Insulin-like Growth Factor-I Promoter Stimulating Cell Growth.
• The present dilemma of adjuvant chemotherapy: acceptance and risks versus benefits.
• Two-step aortic cross-clamping technique for acute type-a aortic dissection in octogenarians.
• [Chronic angioedema and blastocystis hominis infection]
• [Not Available.]